InVivo builds on its up move

Shares of nano cap InVivo Therapeutics (NVIV +20.1%) are up again today on average volume. The up move began on Monday after the company announced the start of a Phase 1 clinical trial for its degradable polymer Neuro-Spinal Scaffold in spinal cord injury patients. Prices have popped over 40% since then.

Investors need to be both patient and cautious here. The clinical trial size is only five subjects and will begin at one site, The University of Arizona in Tuscon, AZ. Two additional sites should come on line in Q2. The regulatory process for this device will be long and arduous.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs